Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability

Joint Bone Spine

Volumn 80, Issue 3, 2013, Pages 258-264

  Lespessailles, Eric ^a  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Bisphosphonates efficacy; Bisphosphonates safety; Glucocorticoid induced osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

ADVERSE OUTCOME; BONE DENSITY; CANCER RISK; CLINICAL FEATURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FRACTURE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY; KIDNEY FAILURE; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINE; TREATMENT DURATION; VASCULITIS; CHEMICALLY INDUCED; OSTEOPOROSIS;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 84878349173     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.08.005     Document Type: Short Survey

References (69)

1. Van Staa T.P., Cooper C., Abenhaim L., et al. Utilisation of oral corticosteroids in the United Kingdom. QJ Med 2000, 93:105-111.
2. Curtis J.R., Westfall A.O., Allison J.J., et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485-2494.
3. Hoes J.N., Jacobs J.W.G., Boers M., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007, 66:1560-1567.
4. Recommandations de bonne pratique: traitement médicamenteux de l'ostéoporose cortisonique. ANSM (anciennement Agence Française de Sécurité Sanitaire des Produits de Santé). édition 2003.
5. Guidelines working group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. Glucocorticoid-induced osteoporosis guidelines for prevention and treatment. London: Royal College of Physicians; 2002.
6. Geusens P.P., de Nijs R.N., Lems W.F., et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004, 63:324-325.
7. Grossman J.M., Gordon R., Ranganath V.K., et al. American College of Rheumatology 2010: recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010, 62:1515-1526.
8. Teitelbaum S., Seton M.P., Saag K.G. Should bisphosphonates be used for long-term treatment of glucorcorticoid-induced osteoporosis?. Arthritis Rheum 2011, 63:325-328.
9. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-299.
10. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-years effects of alendronate on bone mineral density and vertebral fractures in patients receiving glucocorticoids. Arthritis Rheum 2001, 44:202-211.
11. Roux C., Oriente P., Laan R., et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998, 83:1128-1133.
12. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387.
13. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
14. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006-1013.
15. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
16. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteo (HORIZON): a multicentre, bouble-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
17. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
18. Saag K.G., Zanchetta J.R., Devogelaer J.P., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. Arthritis Rheum 2009, 11:3346-3355.
19. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
20. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
21. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1861-1862.
22. Heckbert S.R., Li G., Cummings S.R., et al. Use of Alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
23. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population base case-control study. BMJ 2008, 336:813-816.
24. Karam R., Camm J., Mc Clung M. Yearly zoledronic acid in post-menopausal osteoporosis. N Engl J Med 2007, 357:712-713.
25. Barrett-Connor E., Swern A.S., Hustad C.M., et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trial. Osteoporos Int 2012, 23:233-245.
26. http://www.fda.gov/drug/early_comm/bisphosphonates_update_2008.htm.
27. Abrahamsen B., Eiken P., Brixen K. At rial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581-592.
28. Rhee C.W., Lee J., Oh S., et al. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012, 23:247-254.
29. Marx E.M. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1118.
30. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
31. ANSM (past AFSSAPS). Recommandations on bucco-dental management of patients with bisphosphonates. 2007.
32. Silverman S.L., Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009, 122:S33-S45.
33. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
34. Lane N.E., Yao W., Balooch M., et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466-476.
35. Xia X., Kar R., Gluhak-Heinrich J., et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 2010, 25:2479-2488.
36. Burr D.B., Allen M.R. Mandibular necrosis in beagle dogs treated with bisphosphonate. Orthod Craniofac Res 2009, 12:221-228.
37. Allen M.R. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 2009, 189:289-294.
38. Messer J., Reitman D., Sacks H.S., et al. Association of adrenocorticosteroid therpy and peptic-ulcer disease. N Engl J Med 1983, 309:21-24.
39. Cryer B., Bauer D.C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 2002, 77:1031-1043.
40. Hamilton B., McCoy K., Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003, 14:259-262.
41. Reszka A.A., Halasy-Nagy J., Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001, 59:193-202.
42. Wysowski D.K. Report of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
43. Cush JJ, Dao K. FDA reviews bisphosphonate safety. Drug Saf Q 2011;3:1.
44. Cardwell C.R., Abnet C.C., Cantwell M.M., et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
45. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
46. Homik J., Cranney A., Shea B., et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000, CD001347.
47. Schilcher J., Michaëlsonn K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:28-37.
48. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
49. Bush L.A., Chew F.S. Subtrochanteric femoral insufficiency fracture in women on bisphosphonate therapy for glucocorticoid-induced osteoporosis. Radiol Case Rep 2009, 4. doi:12484/rcr.v4il.261.
50. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
51. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
52. Audran M., Cortet B., Thomas T. What do we know about atypical femoral fracture? Insights and enigmas. Joint Bone Spine 2011, 78:568-571.
53. Rizzoli R., Akesson K., Bouxsein M., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society of Clinical and Economic Aspects of osteoporosis and osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.
54. Klawansky S., Komaroff E., Cavanaugh P.F., et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003, 14:570-576.
55. Sayegh R., Auerbach S.D., Li Xi, et al. GC induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5'-flanking region of the human epithelial sodium channel α subunit gene. J Biol Chem 1999, 274:12431-12437.
56. Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002, 96:23-43.
57. Chang J.T., Green L., Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003, 349:1676-1679.
58. Miller P.D., Roux Ch, Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault Method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20:2105-2115.
59. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
60. Abadie E.C., Devogealer J.P., Ringe J.D., et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum 2005, 35:1-4.
61. Van Staa T.P., Laan F.R., Barton I.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
62. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22:2951-2961.
63. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:1-28.
64. Abrahamsen Bo. Adverse effects of bisphosphonate. Calcif Tissue Int 2010, 86:421-435.
65. Hansen K.E., Wilson H.A., Zapalowski C., et al. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011, 26:1-8.
66. Lane N.E., Yao W. New insights into the biology of glucocorticoid-induced osteoporosis. IBMS Bone Key 2011, 8:229-236.
67. Compston J. Clinical Question: what is the best approach to managing glucocorticoid-induced osteoporosis?. Clin Endocrinol 2011, 74:547-550.
68. Den Uyl D., Bulting I., Lems W. Advances in glucorticoid-induced osteoporosis. Curr Rheumatol Rep 2011, 13:233-240.
69. Lekamwasam S., Adachi J.D., Agnusdei D., et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012, [published on line]. 10.1007/s00198-012-1958-1.